Why the study?
Do new oral anticoagulants (apixaban, dabigatran, rivaroxaban) provide effective alternatives to vitamin K antagonists for the prevention and treatment of thrombotic diseases?
Do new oral anticoagulants (apixaban, dabigatran, rivaroxaban) provide effective alternatives to vitamin K antagonists for the prevention and treatment of thrombotic diseases?
This review provides an overview of the clinical trial data for the novel oral anticoagulants apixaban, dabigatran, and rivaroxaban as alternatives to vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
May guide NOAC selection for VTE, ACS, and AF; leaves open head-to-head comparisons and long-term real-world data.
García et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: